The Effects of Daily Supplementation of Nutriose® on the Fecal Microbiota in Volunteers.

NCT05105425 | Completed

• 1 other identifier: 2020-A03403-36
• Study Type: interventional
• Target: 124
• Locations: 1 country
• Sites: 2

Brief Summary

The effects of daily supplementation of the NUTRIOSE® on the fecal microbiota. The hypothesis of the study is that the NUTRIOSE® is able to modulate the intestinal microbiota in a positive way, compare to a placebo, in healthy volunteers.

Conditions

Healthy Male Volunteers

Keywords

Dietary fiber; Microbiota; Stool collection; Shotgun

Outcome Measures

Primary Outcomes (1)

• Comparison at V3 of relative abundance of Parabacteroides genus in intestinal microbiota

  Assessed via Shotgun metagenomics analysis

  4 weeks

Secondary Outcomes (6)

• Comparison at V4 of relative abundance of Parabacteroides genus in intestinal microbiota.

  7 or 8 weeks

• Comparisons at V3 and V4 of relative abundance of intestinal microbiota (Bacterial species of Parabacteroides genus, Bacteroides genus, Firmicutes phylum, the functional levels of the intestinal microbiota, ...)

  2 weeks

• Comparisons at V3 and V4 of intestinal parameters : Fecal pH

  2 weeks

• Comparisons at V3 and V4 of intestinal parameters: Fecal short chain fatty acids (SCFA)

  2 weeks

• Comparisons at V3 and V4 of intestinal parameters: Secretory immunoglobulin A in feces

  2 weeks

Study Arms (2)

NUTRIOSE®

ACTIVE COMPARATOR

1 sachet to be taken at breakfast during 4 weeks

Dietary Supplement: NUTRIOSE®

GLUCIDEX® IT21

PLACEBO COMPARATOR

1 sachet to be taken at breakfast during 4 weeks

Dietary Supplement: GLUCIDEX® IT21 (Placebo)

Interventions

NUTRIOSE® DIETARY_SUPPLEMENT

After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks. They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).

NUTRIOSE®

GLUCIDEX® IT21 (Placebo) DIETARY_SUPPLEMENT

After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks. They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).

GLUCIDEX® IT21

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male volunteer,
• Age between 18 and 60 years (limits included),
• BMI between 18.5 and 25 kg/m² (limits included),
• Having a high or a low usual fiber consumption,
• With a usual normal intestinal transit. According to stool questionnaire completed between V1 and V2, mean of the 7 days of completion, maximum 3 stools / day and 5 stools/weeks minimum and with mean normal consistency (from type 3 to type 5 of the BSFS and with a tolerance of 1 to 3 stools in deviation /week) according to the investigator's opinion,
• Non-smoking or with tobacco consumption \< 5 cigarettes / day and agreeing to keep his smoking habits unchanged during the all duration of the study,
• Weight stable within ± 5% in the last three months;
• No significant change in food habits or in physical activity in the 3 months before the study and agreeing to keep these habits unchanged throughout the study;
• Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination,
• Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,
• Affiliated with a social security scheme
• Agreeing to be registered on the national file of volunteers in biomedical research file.

You may not qualify if:

• Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder,
• Suffering from gastrointestinal disorders such as celiac disease, Crohn's disease, functional constipation, irritable bowel syndrome or another gastrointestinal found to be inconsistent with the study according to the investigator,
• Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, uncontrolled cardiac disease, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or another severe disorders found to be inconsistent with the conduct of the study by the investigator,
• With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient,
• Lactose intolerant,
• Having undergone recent surgical procedure in the past 6 months or planned in the 2 months to come,
• Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 4 weeks before the V1 visit, i.e. medication with impact on intestinal transit such as anti-diarrheal, anti-spasmodic, antidepressants antibiotics, antacids, laxative, antifungal, NSAI, antivomiting, corticoids, opioids, narcotic analgesic and biliary acids chelator, and chronic hormonal treatment started less than 3 months ago (i.e. new method of hormonal contraception, thyroidal trouble treatment)
• With a current or planned in the next 3 months specific diet (hyper or hypocaloric, vegan, vegetarian…) or stopped less than 3 months before the study,
• With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,
• Consuming more than 3 standard drinks of alcoholic beverage or not agreeing to keep his alcohol consumption habits unchanged throughout the study,
• Having a lifestyle deemed incompatible with the study according to the investigator including high level physical activity (defined as more than 10 hours of significant physical activity a week, walking excluded),
• Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros,
• Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
• Presenting a psychological or linguistic incapability to sign the informed consent,
• Impossible to contact in case of emergency.

Sponsors & Collaborators

• Roquette Freres: lead
• BioFortis: collaborator

Study Sites (2)

Clinical Investigation Unit of Biofortis Paris

Paris, 75012, France

Location

Clinical Investigation Unit of Biofortis

Saint-Herblain, 44800, France

Location

MeSH Terms

Interventions

NUTRIOSE

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED PILOT STUDY
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2021
• First Posted: November 3, 2021
• Study Start: July 19, 2021
• Primary Completion: August 7, 2023
• Study Completion: August 7, 2023
• Last Updated: April 25, 2024

Record last verified: 2024-04

Locations

FR (2)